Alzheimer's Clinical Trial Consortium (ACTC) Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2020
NCT04468659
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Alzheimer's Clinical Trial Consortium (ACTC) | Alzheimer's Clinical Trials Consortium

Active Ingredients

Drugs in Phase 3 Trials (1)

LECANEMAB (Leqembi) (1 trial)

Drugs in Phase 2 Trials (3)

cannabidiol (Epidiolex) (1 trial)

ct1812 (1 trial)

tetrahydrocannabinol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Amyloidosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4